At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
0.5mg Ranibizumab +1 moredrug
Likely dose
0.5mg Ranibizumabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.
In Brief
A Phase 4 clinical trial evaluating 0.5mg Ranibizumab and Targeted Pan Retinal Photocoagulation for Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions. Completed, enrolled 30 participants across 3 sites.
Detailed Summary
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch retinal vein occlusions compared to standard of care
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedOct 2012
Primary CompletionOct 2015
TodayJul 2026
First PostedOct 19, 2012
Enrollment StartOct 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 13.7 years ago
Interventions
0.5mg Ranibizumabdrug
intravitreal injections
Targeted Pan Retinal Photocoagulationprocedure
Targeted Pan Retinal Photocoagulation based on wide field angiography